Plus Therapeutics (CNSY) Stock Price, News & Analysis

Company Overview

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics is advancing 186RNL through clinical development and has not established a portfolio of marketed products.

Based in Austin, Texas, Plus Therapeutics conducts its development activities primarily through clinical research in the United States. The company is led by Marc H. Hedrick, M.D., who serves as president and chief executive officer.

Key Stats

• Today's Range: $4.00 to $4.00
• 50-Day Range: N/A
• 52-Week Range: $2.90 to $23.42
• Volume: 934 shs
• Average Volume: 317,178 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CNSY
• CIK: N/A
• Web: N/A
• Phone: (737) 255-7194
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A